In the ongoing quest for more personalized and effective cancer treatments, Leverkusen, Germany-based Bayer AG is partnering with Roche Holding AG's Foundation Medicine Inc. (FMI) to develop genetic sequencing tests to identify patients who might benefit from various approved and investigational cancer therapies.